SCHEMBL13814501

SCHEMBL13814501

COc1ccc2c(O)c3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 8/20 0.76
EP300 Q09472 4/20 0.65
ALDH1A1 P00352 2/20 0.65
LMNA P02545 2/20 0.65
BCHE P06276 2/20 0.65
CYP3A4 P08684 2/20 0.65
CYP2D6 P10635 2/20 0.65
MAPT P10636 2/20 0.65
CHRM1 P11229 2/20 0.65
DRD2 P14416 2/20 0.65
TSHR P16473 2/20 0.65
ADRA2B P18089 2/20 0.65
ADRA2C P18825 2/20 0.65
RXRA P19793 2/20 0.65
DRD1 P21728 2/20 0.65
ACHE P22303 2/20 0.65
HTR2B P41595 2/20 0.65
HTT P42858 2/20 0.65
RAD52 P43351 2/20 0.65
KCNH2 Q12809 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13814556 0.90 P2RX7 (0.81) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL299398 0.88 P2RX7 (0.78) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL31214707 0.88 P2RX7 (0.78) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL298305 0.87 P2RX7 (1.00) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL13814557 0.85 P2RX7 (0.70) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL14513612 0.85 P2RX7 (0.89) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL14513594 0.85 P2RX7 (0.79) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL14513599 0.83 P2RX7 (0.62) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL13814544 0.82 P2RX7 (0.81) P2RX7EP300ALDH1A1LMNABCHE
SCHEMBL14513605 0.82 P2RX7 (0.84) P2RX7EP300ALDH1A1LMNABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2070926-A1 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2009-06-17 EP disclosed
US-20070098649-A1 Method and composition for controlling oral pathogens THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070098649-A1 Method and composition for controlling oral pathogens BROX, NOP2, FBL P2RX7 2447/4885EP300 3990/4885ALDH1A1 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.